➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,528,143

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,528,143 protect, and when does it expire?

Patent 7,528,143 protects INREBIC and is included in one NDA.

This patent has forty-two patent family members in twenty-five countries.

Summary for Patent: 7,528,143
Title:Bi-aryl meta-pyrimidine inhibitors of kinases
Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. ##STR00001##
Inventor(s): Noronha; Glenn (Oceanside, CA), Mak; Chi Ching (San Diego, CA), Cao; Jianguo (San Diego, CA), Renick; Joel (San Diego, CA), McPherson; Andrew (San Diego, CA), Zeng; Binqi (San Diego, CA), Pathak; Ved P. (San Diego, CA), Lohse; Daniel L. (San Diego, CA), Hood; John D. (San Diego, CA), Soll; Richard M. (San Diego, CA)
Assignee: TargeGen, Inc. (San Diego, CA)
Application Number:11/588,638
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,528,143

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Impact INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,528,143

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006309013   Start Trial
Brazil PI0618179   Start Trial
Canada 2628283   Start Trial
China 101370792   Start Trial
China 103626742   Start Trial
Cyprus 1118330   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.